

Matteo Castelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7322096/publications.pdf>

Version: 2024-02-01

25
papers

1,907
citations

516561

16
h-index

552653

26
g-index

31
all docs

31
docs citations

31
times ranked

3917
citing authors

#	ARTICLE	IF	CITATIONS
1	Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets. Nature Nanotechnology, 2013, 8, 594-601.	15.6	1,260
2	Viral Respiratory Pathogens and Lung Injury. Clinical Microbiology Reviews, 2021, 34, .	5.7	76
3	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut, 2016, 65, 512-523.	6.1	67
4	Interferon-Î2-1a Inhibition of Severe Acute Respiratory Syndromeâ€“Coronavirus 2 In Vitro When Administered After Virus Infection. Journal of Infectious Diseases, 2020, 222, 722-725.	1.9	61
5	Salts drive controllable multilayered upright assembly of amyloid-like peptides at mica/water interface. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8543-8548.	3.3	46
6	Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens. International Journal of Molecular Sciences, 2012, 13, 8273-8292.	1.8	37
7	Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools. Drug Discovery Today, 2013, 18, 464-471.	3.2	32
8	A Biologically-validated HCV E1E2 Heterodimer Structural Model. Scientific Reports, 2017, 7, 214.	1.6	32
9	Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Science Advances, 2020, 6, eabb5938.	4.7	29
10	HCV E2 core structures and mAbs: something is still missing. Drug Discovery Today, 2014, 19, 1964-1970.	3.2	27
11	Neutralization Interfering Antibodies: A â€œNovelâ€“Example of Humoral Immune Dysfunction Facilitating Viral Escape?. Viruses, 2012, 4, 1731-1752.	1.5	26
12	Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides. Clinical and Developmental Immunology, 2013, 2013, 1-12.	3.3	26
13	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. Journal of Virology, 2019, 93, .	1.5	21
14	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. Nature Structural and Molecular Biology, 2021, 28, 662-670.	3.6	19
15	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. Frontiers in Microbiology, 2020, 11, 1704.	1.5	18
16	Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. New Microbiologica, 2012, 35, 399-406.	0.1	13
17	Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Reports, 2022, 39, 110859.	2.9	13
18	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses, 2021, 13, 1514.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs. <i>Nucleic Acids Research</i> , 2022, 50, 3475-3489.	6.5	12
20	Role and potential therapeutic use of antibodies against herpetic infections. <i>Clinical Microbiology and Infection</i> , 2017, 23, 381-386.	2.8	11
21	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. <i>Vaccines</i> , 2021, 9, 291.	2.1	11
22	Influenza B-Cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines. <i>Viruses</i> , 2012, 4, 3090-3108.	1.5	10
23	Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle. <i>Antiviral Research</i> , 2018, 151, 71-77.	1.9	9
24	New perspectives in cancer drug development: computational advances with an eye to design. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1491-1502.	1.7	6
25	Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. <i>Virology Journal</i> , 2020, 17, 103.	1.4	4